CAS 1275595-86-2

Selatinib

Description:

Selatinib is a small molecule inhibitor primarily targeting the epidermal growth factor receptor (EGFR) and is classified as a tyrosine kinase inhibitor. It is designed to interfere with the signaling pathways that promote cell proliferation and survival, making it a potential therapeutic agent in the treatment of certain cancers, particularly those with mutations in the EGFR gene. Selatinib exhibits characteristics typical of many kinase inhibitors, including a relatively low molecular weight and the ability to penetrate cell membranes effectively. Its mechanism of action involves binding to the ATP-binding site of the EGFR, thereby inhibiting its kinase activity and blocking downstream signaling pathways. The compound is often studied in the context of personalized medicine, as its efficacy may vary based on specific genetic mutations present in tumors. Additionally, like many pharmaceuticals, selatinib may have a range of side effects and interactions, necessitating careful monitoring during treatment. Overall, its development reflects ongoing efforts to target specific molecular pathways in cancer therapy.

Formula: C₂₉H₂₆ClFN₄O₃S

Synonyms:

• N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfinyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine
• Selatinib

Selatinib

CAS: 1275595-86-2

Selatinib

Purity: ≥98%

Molecular weight: 565.06g/mol

Ref: 54-BUP00710

Selatinib

CAS: 1275595-86-2

Formula: C₂₉H₂₆ClFN₄O₃S

Molecular weight: 565.06

Ref: 4Z-S-226001

Selatinib

CAS: 1275595-86-2

Selatinib is a pyridine compound that inhibits the tyrosine kinase activity of proteins. Selatinib has been shown to inhibit the growth of cancer cells in vitro and in vivo, as well as inhibit tumor cell proliferation. Selatinib has also been shown to be selective for phosphorylation of EGFR, which is essential for the regulation of cellular proliferation. Selatinib binds to the ATP-binding site on EGFR and prevents ATP from binding, thereby inhibiting kinase activity. This leads to inhibition of cell proliferation and apoptosis induction.

Formula: C₂₉H₂₆ClFN₄O₃S

Purity: Min. 95%

Molecular weight: 565.1 g/mol

Ref: 3D-FS180427

Lapatinib-d7 Sulfoxide Dihydrochloride

Controlled Product

CAS: 1275595-86-2, 1611495-33-0

Applications Lapatinib-d7 Sulfoxide Dihydrochloride is a by-product during the synthesis of Lapatinib-d7 Dihydrochloride (L175807), a labeled Lapatinib (L175800), a reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Antineoplastic.
References Kim, T.E., et al.: Drugs, 6, 886 (2003); Wood, E.R., et al.: Cancer Res., 64, 6652 (2004); Spector, N.L., et al.: J. Clin. Oncol., 23, 2502 (2005)

Formula: C₂₉H₁₉D₇ClFN₄O₃S·2(HCl)

Color and Shape: Neat

Molecular weight: 645.02

Ref: TR-L175812

Selatinib

CAS: 1275595-86-2

Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.

Formula: C₂₉H₂₆ClFN₄O₃S

Purity: 98.00%

Color and Shape: Solid

Molecular weight: 565.06

Ref: TM-T34602